MedTrace Logo

The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics

NCT04831151 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-05-19

No results posted yet for this study

Summary

The aim of this study is to determine the effect of the treatment of polycystic ovary syndrome with two different oral contraceptives that contain cyproterone acetate and drospirenone

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Yasmin

Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone

DRUG

Diane-35

Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate

Sponsors & Collaborators

  • Inonu University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-03-31
Completion
2023-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04831151 on ClinicalTrials.gov